Ellie Jhun1, Ying He, Yingwei Yao, Robert E Molokie, Diana J Wilkie, Zaijie Jim Wang. 1. From the *Department of Biopharmaceutical Sciences, University of Illinois at Chicago College of Pharmacy; †Department of Biobehavioral Health Science, University of Illinois at Chicago College of Nursing; ‡Division of Hematology/Oncology, University of Illinois at Chicago College of Medicine; §Jesse Brown Veteran's Administration Medical Center; and ∥Cancer Center, University of Illinois at Chicago, Chicago, Illinois.
Abstract
BACKGROUND: Pain in sickle cell disease (SCD) is characterized by episodes of acute pain, primarily responsible for acute health care utilization, and persistent chronic pain. Pain severity and frequency vary significantly among patients with SCD. In this study, we investigated the possible contribution of monoamine gene polymorphisms to pain variation. METHODS: Adult subjects with SCD completed PAINReportIt, a computerized McGill Pain Questionnaire, from which we calculated the Composite Pain Index. Utilization data were obtained from the medical record and biweekly telephone calls for 12 months. Utilization is defined as admissions to the emergency department and/or the acute care center resulting from a sickle cell pain crisis. We performed genotyping for catechol-O-methyltransferase (COMT) Val158Met (rs4680) and dopamine D3 receptor (DRD3) Ser9Gly (rs6280) polymorphisms, which were analyzed for associations with pain phenotypes. RESULTS: Binary logistic models revealed that DRD3 Ser9Gly heterozygote patients were more likely not to have an acute pain crisis (odds ratio [OR] [95% confidence interval {CI}], 4.37 [1.39-22.89]; P = 0.020), which remained so when demographic variables were considered (OR [95% CI], 4.53 [1.41-28.58]; P = 0.016). COMT Val158Met Met allele showed lower probability for zero utilization (OR [95% CI], 0.32 [0.12-0.83]; P = 0.020) than the Val allele. In the negative binomial regression analysis, subjects with COMT Met/Met genotype had utilization incident rate ratio (95% CI) of 2.20 (1.21-3.99) over those with Val/Val (P = 0.010). CONCLUSIONS: These exploratory findings suggest that DRD3 Ser9Gly and COMT Val158Met may contribute to pain heterogeneity in SCD, as suggested by the different rates of acute pain crisis. Specifically, SCD patients with the DRD3 homozygote genotypes, COMT 158 Met allele or Met/Met genotype, are more likely to have acute care utilization, an indicator of acute pain. These results, however, will need to be further examined in future large prospective studies.
BACKGROUND:Pain in sickle cell disease (SCD) is characterized by episodes of acute pain, primarily responsible for acute health care utilization, and persistent chronic pain. Pain severity and frequency vary significantly among patients with SCD. In this study, we investigated the possible contribution of monoamine gene polymorphisms to pain variation. METHODS: Adult subjects with SCD completed PAINReportIt, a computerized McGill Pain Questionnaire, from which we calculated the Composite Pain Index. Utilization data were obtained from the medical record and biweekly telephone calls for 12 months. Utilization is defined as admissions to the emergency department and/or the acute care center resulting from a sickle cell pain crisis. We performed genotyping for catechol-O-methyltransferase (COMT) Val158Met (rs4680) and dopamine D3 receptor (DRD3) Ser9Gly (rs6280) polymorphisms, which were analyzed for associations with pain phenotypes. RESULTS: Binary logistic models revealed that DRD3 Ser9Gly heterozygote patients were more likely not to have an acute pain crisis (odds ratio [OR] [95% confidence interval {CI}], 4.37 [1.39-22.89]; P = 0.020), which remained so when demographic variables were considered (OR [95% CI], 4.53 [1.41-28.58]; P = 0.016). COMTVal158Met Met allele showed lower probability for zero utilization (OR [95% CI], 0.32 [0.12-0.83]; P = 0.020) than the Val allele. In the negative binomial regression analysis, subjects with COMT Met/Met genotype had utilization incident rate ratio (95% CI) of 2.20 (1.21-3.99) over those with Val/Val (P = 0.010). CONCLUSIONS: These exploratory findings suggest that DRD3 Ser9Gly and COMTVal158Met may contribute to pain heterogeneity in SCD, as suggested by the different rates of acute pain crisis. Specifically, SCDpatients with the DRD3 homozygote genotypes, COMT 158 Met allele or Met/Met genotype, are more likely to have acute care utilization, an indicator of acute pain. These results, however, will need to be further examined in future large prospective studies.
Authors: Miriam O Ezenwa; Robert E Molokie; Zaijie Jim Wang; Yingwei Yao; Marie L Suarez; Veronica Angulo; Diana J Wilkie Journal: J Pain Symptom Manage Date: 2014-03-15 Impact factor: 3.612
Authors: O S Platt; B D Thorington; D J Brambilla; P F Milner; W F Rosse; E Vichinsky; T R Kinney Journal: N Engl J Med Date: 1991-07-04 Impact factor: 91.245
Authors: Jon-Kar Zubieta; Mary M Heitzeg; Yolanda R Smith; Joshua A Bueller; Ke Xu; Yanjun Xu; Robert A Koeppe; Christian S Stohler; David Goldman Journal: Science Date: 2003-02-21 Impact factor: 47.728
Authors: Diana J Wilkie; M Kay M Judge; Donna L Berry; Jean Dell; Shiping Zong; Rudy Gilespie Journal: J Pain Symptom Manage Date: 2003-03 Impact factor: 3.612
Authors: Susan W Wesmiller; Susan M Sereika; Catherine M Bender; Dana Bovbjerg; Gretchen Ahrendt; Marguerite Bonaventura; Yvette P Conley Journal: Auton Neurosci Date: 2016-09-28 Impact factor: 3.145
Authors: Ellie H Jhun; Yingwei Yao; Ying He; A Kyle Mack; Diana J Wilkie; Robert E Molokie; Zaijie Jim Wang Journal: Pharmacogenomics Date: 2015-11-10 Impact factor: 2.533
Authors: Evadnie Rampersaud; Guolian Kang; Lance E Palmer; Sara R Rashkin; Shuoguo Wang; Wenjian Bi; Nicole M Alberts; Doralina Anghelescu; Martha Barton; Kirby Birch; Nidal Boulos; Amanda M Brandow; Russell John Brooke; Ti-Cheng Chang; Wenan Chen; Yong Cheng; Juan Ding; John Easton; Jason R Hodges; Celeste K Kanne; Shawn Levy; Heather Mulder; Ashwin P Patel; Latika Puri; Celeste Rosencrance; Michael Rusch; Yadav Sapkota; Edgar Sioson; Akshay Sharma; Xing Tang; Andrew Thrasher; Winfred Wang; Yu Yao; Yutaka Yasui; Donald Yergeau; Jane S Hankins; Vivien A Sheehan; James R Downing; Jeremie H Estepp; Jinghui Zhang; Michael DeBaun; Gang Wu; Mitchell J Weiss Journal: Blood Adv Date: 2021-07-27